SCHEDULE: Longitude Capital Discloses 7% Stake in CytomX

Longitude Capital and its affiliates have reported a 7% beneficial ownership stake in CytomX Therapeutics, Inc.

Summary

• Longitude Capital Partners V, LLC and Longitude 103.8 East Partners, LLC, along with their respective funds and managing members Patrick G. Enright and Juliet Tammenoms Bakker, filed a Schedule 13G.
• The reporting persons collectively beneficially own 15,288,461 shares of CytomX Therapeutics common stock.
• This ownership represents approximately 7.0% of the total 217,702,919 outstanding shares reported by the issuer as of April 30, 2026.
• The filing clarifies that the shares are held by Longitude Venture Partners V, L.P. (12,458,461 shares) and Longitude 103.8 East, L.P. (2,830,000 shares).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing reflecting existing institutional investment positions rather than a change in company strategy or performance.

Positives

• Institutional backing from a specialized life sciences venture capital firm indicates long-term confidence in the company's pipeline.
• The filing confirms the reporting persons do not intend to change or influence the control of the issuer.

Negatives

• The disclosure notes a potential 'group' relationship with Seven Fleet Advisors LLC due to shared policies and procedures, which adds complexity to the ownership structure.

Risks

• The reporting persons disclaim beneficial ownership of shares held by Seven Fleet Advisors, highlighting potential regulatory scrutiny regarding group status under Section 13(d)(3) of the Exchange Act.

Future Outlook

The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory disclosure for institutional investors in the biotechnology sector, reflecting typical portfolio management activities by venture capital firms.

Comparison to Industry Standards

• The 7% ownership stake is consistent with typical venture capital holdings in mid-stage biotech companies.
• The filing follows standard SEC Schedule 13G reporting requirements for passive investors.

Stakeholder Impact

• Shareholders should note the concentration of ownership among Longitude Capital entities.
• Potential for future market volatility if the reporting persons decide to adjust their position.

Next Steps

• The reporting persons will continue to monitor their investment in accordance with their internal policies and regulatory requirements.

Key Dates

Keywords

CytomX Therapeutics, Longitude Capital, Schedule 13G, Beneficial Ownership, Biotech Investment, CTMX